Razoxane in treatment of acute myeloid leukaemia Razoxane (ICRF 159; 1, propane, Cl ,H16N404) has been used for treating acute leukaemia.' It is thought to act as an inhibitor of RNA, or more likely of DNA, and to interfere with cell division at the G2/M phase of the cell cycle.2 After recent claims of success with razoxane and cystosine in treating acute myeloid leukaemia and the relative absence of side effects, we decided to treat consecutive and unselected patients with acute myeloid leukaemia with this combination.
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We obtained poor remission results. Thirteen of the 17 patients died. None of these patients had more than four courses of treatment. The main cause of death was haemorrhage or septicaemia. Of the four patients who are alive, only two entered remission. One of these did not respond to five courses initially but remission was obtained after four courses at the higher dosage. In the other patient bone marrow aspiration was difficult because of the presence of reticulin. After nine courses she was judged to be in remission by her excellent clinical condition and normal peripheral blood count, but confirmation by bone marrow examination is lacking. Both these patients remain well on maintenance treatment.
The two patients with CML in acute blast transformation remained reasonably well initially. One of them could not tolerate further treatment owing to severe nausea and vomiting and treatment was discontinued. The other has remained well with this combination and has received 12 courses of treatment altogether. It is now 27 weeks since blast transformation was first diagnosed. She requires transfusions every 10 days but apart from that has no haemorrhagic or infective complications.
The total white cell count, platelets, and the blast count in the peripheral blood dropped after the first course of treatment (figure) . With subsequent courses the neutrophil count rose moderately. Platelet counts fell progressively with each course of treatment with no subsequent rise, except in the two patients who entered remission.
Every patient complained of nausea and vomiting of varying severity. One patient complained of calf pain related to treatment, but the blood urea and electrolyte concentrations and the results of neurological examination were normal. None of our patients developed alopecia.
Comment
These results indicate that when used in this way razoxane is not satisfactory treatment for acute myeloid leukaemia. We would recommend that it should only be used when other regimens have failed. Although remission was achieved in one (possibly two) cases, the dose of cytarabine was such that the remission could have been due to that drug alone. Our response and remission rates were no better than those previously obtained in this department using cytarabine alone.3
The results obtained in CML in blast crisis were encouraging.
Since the resultjs of treatment in this group of patients is usually unsatisfactory, further trials with razoxane in combination with cytarabine and other drugs known to be partially effective in this disease-for example, vincristine-should be undertaken.
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The present study has shown that there is a highly significant association between URTIs and a relapse of either UC or CD. Thus 60% of patients with UC with a relapse had had an URTI during the previous month compared with 22-7 % of patients who presented in remission. A similar relationship was present in patients with CD. Of the other precipitating factors investigated, none appeared with sufficient frequency to enable meaningful results to be obtained.
The reasons why URTIs should be associated with a relapse of either UC or CD are uncertain. One hypothesis is that circulating immune complexes resulting from the infection may be deposited in the diseased intestine. In rabbits deposition of immune complexes in the colon may 
Presumed ataxia-telangiectasia in a man
Ataxia-telangiectasia is a complex, multisystem genetic disorder.' 2 It is usually fatal from uncontrolled infection in adolescence, though it shows some variability in severity, age of onset, and rate of progression. We report an unusual case of the condition, resembling Friedreich's ataxia, in a man.
Case report
The patient is a 37-year-old Italian lawyer with two children, who has been diabetic from the age of 35. His parents were first cousins, and there had been consanguineous marriages in previous generations. From infancy he had had recurrent infective diarrhoea and subsequently recurrent respiratory and urinary infections. He had had two operations for hypospadias in infancy, but his early development had otherwise been normal. Neurological symptoms began in his late teens, with weakness and wasting beginning distally in legs, later spreading proximally. Progressive ataxia developed later, though on 30 October 1977 he still walked unaided. He complained of "hypersensitivity" of the skin of the feet and legs.
His paternal grandfather and great-grandfather had had progressive walking difficulty and required wheelchairs in old age. In 1976 his father, though asymptomatic, had impaired proprioceptive sensation in the legs and an absent left ankle jerk.
The patient had telangiectases in both popliteal fossae, gonadal atrophy, bilateral pes cavus, and normal intellect. He had fine, phasic horizontal nystagmus on lateral gaze bilaterally; the eye movements were otherwise normal, as were the remaining cranial nerves. There were no bulbar conjunctival lesions. 
Comment
In our view the telangiectasia, deficiency of IgA, and raised alphafetoprotein concentration confirm the diagnosis ofataxia-telangiectasia. The onset of neurological symptoms was late, the course relatively benign, and the predominance of the peripheral neuropathy unusual.
Cases have been reported with survival into the fifth decade,3 presumably owing to the increasingly effective treatment of infection. Evidence of cerebellar dysfunction in our patient was slight, but in one report' cerebellar dysfunction was minimal at the age of 34. Usually cerebellar ataxia is the predominant neurological manifestation, beginning in childhood. Nevertheless, peripheral neuropathy5 certainly occurs in this condition and in our patient was the initial and predominant neurological manifestation.
The nature of the disorder present in previous generations is unknown but the pattern suggests pseudo-dominant inheritance due to multiple consanguinity since ataxia-telangiectasia is usually due to an autosomal recessive gene. Though our patient and his relatives possibly suffered from a previously unreported hereditary axonal neuropathy associated with telangiectasia, immune deficiency, and a raised serum ac-fetoprotein concentration, on balance we believe that it was probably an atypical presentation of ataxia-telangiectasia.
